CN106491852A - 一种用于治疗急性发热的药物及其制备方法 - Google Patents
一种用于治疗急性发热的药物及其制备方法 Download PDFInfo
- Publication number
- CN106491852A CN106491852A CN201611107172.4A CN201611107172A CN106491852A CN 106491852 A CN106491852 A CN 106491852A CN 201611107172 A CN201611107172 A CN 201611107172A CN 106491852 A CN106491852 A CN 106491852A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- mixture
- medicine
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 47
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 22
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 239000001913 cellulose Substances 0.000 claims abstract description 15
- 229920002678 cellulose Polymers 0.000 claims abstract description 15
- 239000002671 adjuvant Substances 0.000 claims abstract description 14
- 229930003231 vitamin Natural products 0.000 claims abstract description 14
- 235000013343 vitamin Nutrition 0.000 claims abstract description 14
- 239000011782 vitamin Substances 0.000 claims abstract description 14
- 229940088594 vitamin Drugs 0.000 claims abstract description 14
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 14
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 13
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 13
- 229940072651 tylenol Drugs 0.000 claims abstract description 13
- 241000202726 Bupleurum Species 0.000 claims abstract description 12
- 239000002245 particle Substances 0.000 claims abstract description 12
- 229930182555 Penicillin Natural products 0.000 claims abstract description 11
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract description 11
- 229940049954 penicillin Drugs 0.000 claims abstract description 11
- 229960003080 taurine Drugs 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 37
- 239000000047 product Substances 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 229940024606 amino acid Drugs 0.000 claims description 13
- 235000010980 cellulose Nutrition 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003448 Vitamin K Natural products 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019168 vitamin K Nutrition 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- 229940046010 vitamin k Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 238000009776 industrial production Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 description 12
- 238000007654 immersion Methods 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
- A61K36/855—Clerodendrum, e.g. glorybower
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种用于治疗急性发热的药物，由以下原料按照重量份组成：辅料2‑5份、牛磺酸5‑10份、纤维素0.5‑3份、维生素0.1‑1.5份、氨基酸1‑6份、泰诺林5‑10份、布洛芬2‑6份、大青叶汁液4‑9份、体积分数为50‑60％的乙醇溶液15‑24份、青霉素1.5‑4份和柴胡颗粒3‑6份。本发明还公布了该药物的制备方法。本发明原料来源广泛，制备工艺简单，适用于大规模的工业化生产；本发明中大青叶汁液、柴胡颗粒、泰诺林、布洛芬等组分起协同作用，配方合理，使用方便，治疗率和有效率均优于现有产品，没有毒副作用，使用效果好。
Description
技术领域
本发明涉及一种常用药物，具体是一种用于治疗急性发热的药物。
背景技术
每当气温急剧变化的时候，许多人就会因为身体抵抗力弱、没有及时增加或减少衣物等原因生病，其中又以感冒、咳嗽和发热最为常见。发热，又称发烧，是发热是由于发热激活物作用于机体，进而导致内生致热原(EP)的产生并入脑作用于体温调节中枢，更进而导致发热中枢介质的释放继而引起调定点的改变，最终引起的调节性体温升高(超过0.5℃)，发热同时常伴有头昏头晕、头痛、乏力食欲减退等非特异症状，引起发热的原因很多，最常见的是感染(包括各种细菌感染，病毒感染，支原体感染等)，其次是结缔组织病(即胶原病)、恶性肿瘤等。发热根据热程热型与临床特点，可分为急性发热(热程小于2周)、长期发热(热程超过2周且多次体温在38℃以上)和反复发热(周期热)。急性发热是人们最常见的一种发热，目前人们都是采用退烧药治疗急性发热，但是现有的退烧药的治疗效果不好，治疗时间长，治疗不彻底，这就为患者带来了痛苦。
发明内容
本发明的目的在于提供一种用于治疗急性发热的药物，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种用于治疗急性发热的药物，由以下原料按照重量份组成：辅料2-5份、牛磺酸5-10份、纤维素0.5-3份、维生素0.1-1.5份、氨基酸1-6份、泰诺林5-10份、布洛芬2-6份、大青叶汁液4-9份、体积分数为50-60％的乙醇溶液15-24份、青霉素1.5-4份和柴胡颗粒3-6份，大青叶汁液采用大青叶浸泡在5-8倍的质量分数为70％的乙醇中2-4次，每次浸泡4-5小时，合并浸泡液并且过滤，收集滤液得到。
作为本发明进一步的方案：辅料采用淀粉、乳糖、糊精、木糖醇、微粉硅胶、蔗糖和葡萄糖的一种或者几种的混合物，纤维素采用微晶纤维素或者羧甲基纤维素。
作为本发明进一步的方案：维生素采用维生素A、维生素B1、维生素C和维生素K的一种或者几种的混合物，氨基酸采用丝氨酸、赖氨酸、谷氨酸和天冬氨酸的一种或者几种的混合物。
所述用于治疗急性发热的药物的制备方法，具体步骤如下：
步骤一，将泰诺林、布洛芬和柴胡颗粒混合在一起并且采用粉碎机粉碎，粉碎后的产物过30-50目筛子，得到第一混合物，留作备用；
步骤二，将牛磺酸、纤维素、维生素、氨基酸和青霉素放入乙醇溶液中，搅拌机在35-48摄氏度下以60-120rpm的转速搅拌20-45分钟，再进行减压浓缩至1:1，静置10-16小时后进行过滤，得到上清液和沉淀物；
步骤三，将大青叶汁液加入上清液中并且搅拌机在常温下以180-300rpm的转速搅拌50-90分钟，将搅拌均匀的产物放入干燥箱中，干燥箱在45-60摄氏度下进行干燥，得到第二混合物；
步骤四，将第一混合物、沉淀物和第二混合物混合均匀并且粉碎，再加入辅料制成胶囊剂、颗粒型冲剂或者片剂即可。
与现有技术相比，本发明的有益效果是：本发明原料来源广泛，制备工艺简单，适用于大规模的工业化生产；本发明中大青叶汁液、柴胡颗粒、泰诺林、布洛芬等组分起协同作用，配方合理，使用方便，治疗率和有效率均优于现有产品，没有毒副作用，使用效果好。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种用于治疗急性发热的药物，由以下原料按照重量份组成：辅料2份、牛磺酸5份、纤维素0.5份、维生素0.1份、氨基酸1份、泰诺林5份、布洛芬2份、大青叶汁液4份、体积分数为52％的乙醇溶液15份、青霉素1.5份和柴胡颗粒3份，大青叶汁液采用大青叶浸泡在6倍的质量分数为70％的乙醇中3次，每次浸泡4小时，合并浸泡液并且过滤，收集滤液得到。辅料采用淀粉、乳糖、木糖醇和蔗糖的混合物，纤维素采用微晶纤维素。
所述用于治疗急性发热的药物的制备方法，具体步骤如下：
步骤一，将泰诺林、布洛芬和柴胡颗粒混合在一起并且采用粉碎机粉碎，粉碎后的产物过30目筛子，得到第一混合物，留作备用；
步骤二，将牛磺酸、纤维素、维生素、氨基酸和青霉素放入乙醇溶液中，搅拌机在35摄氏度下以60rpm的转速搅拌20分钟，再进行减压浓缩至1:1，静置10小时后进行过滤，得到上清液和沉淀物；
步骤三，将大青叶汁液加入上清液中并且搅拌机在常温下以180rpm的转速搅拌60分钟，将搅拌均匀的产物放入干燥箱中，干燥箱在50摄氏度下进行干燥，得到第二混合物；
步骤四，将第一混合物、沉淀物和第二混合物混合均匀并且粉碎，再加入辅料制成胶囊剂、颗粒型冲剂或者片剂即可。
实施例2
一种用于治疗急性发热的药物，由以下原料按照重量份组成：辅料3.5份、牛磺酸7份、纤维素1.5份、维生素0.6份、氨基酸3份、泰诺林8份、布洛芬4份、大青叶汁液6份、体积分数为60％的乙醇溶液21份、青霉素3份和柴胡颗粒5份，大青叶汁液采用大青叶浸泡在8倍的质量分数为70％的乙醇中2次，每次浸泡4.5小时，合并浸泡液并且过滤，收集滤液得到。维生素采用维生素A和维生素C的混合物，氨基酸采用丝氨酸和天冬氨酸的混合物。
所述用于治疗急性发热的药物的制备方法，具体步骤如下：
步骤一，将泰诺林、布洛芬和柴胡颗粒混合在一起并且采用粉碎机粉碎，粉碎后的产物过40目筛子，得到第一混合物，留作备用；
步骤二，将牛磺酸、纤维素、维生素、氨基酸和青霉素放入乙醇溶液中，搅拌机在42摄氏度下以80rpm的转速搅拌35分钟，再进行减压浓缩至1:1，静置13小时后进行过滤，得到上清液和沉淀物；
步骤三，将大青叶汁液加入上清液中并且搅拌机在常温下以240rpm的转速搅拌75分钟，将搅拌均匀的产物放入干燥箱中，干燥箱在50摄氏度下进行干燥，得到第二混合物；
步骤四，将第一混合物、沉淀物和第二混合物混合均匀并且粉碎，再加入辅料制成胶囊剂、颗粒型冲剂或者片剂即可。
实施例3
一种用于治疗急性发热的药物，由以下原料按照重量份组成：辅料5份、牛磺酸10份、纤维素3份、维生素1.5份、氨基酸6份、泰诺林10份、布洛芬6份、大青叶汁液9份、体积分数为60％的乙醇溶液24份、青霉素4份和柴胡颗粒6份，大青叶汁液采用大青叶浸泡在8倍的质量分数为70％的乙醇中3次，每次浸泡4小时，合并浸泡液并且过滤，收集滤液得到。辅料采用淀粉、乳糖、糊精、木糖醇、微粉硅胶、蔗糖和葡萄糖的混合物，纤维素采用羧甲基纤维素。维生素采用维生素A、维生素B1、维生素C和维生素K的混合物，氨基酸采用丝氨酸、赖氨酸、谷氨酸和天冬氨酸的混合物。
所述用于治疗急性发热的药物的制备方法，具体步骤如下：
步骤一，将泰诺林、布洛芬和柴胡颗粒混合在一起并且采用粉碎机粉碎，粉碎后的产物过50目筛子，得到第一混合物，留作备用；
步骤二，将牛磺酸、纤维素、维生素、氨基酸和青霉素放入乙醇溶液中，搅拌机在48摄氏度下以120rpm的转速搅拌35分钟，再进行减压浓缩至1:1，静置16小时后进行过滤，得到上清液和沉淀物；
步骤三，将大青叶汁液加入上清液中并且搅拌机在常温下以300rpm的转速搅拌60分钟，将搅拌均匀的产物放入干燥箱中，干燥箱在60摄氏度下进行干燥，得到第二混合物；
步骤四，将第一混合物、沉淀物和第二混合物混合均匀并且粉碎，再加入辅料制成胶囊剂、颗粒型冲剂或者片剂即可。
选择400个病人，随机平均分为1-4组，每组100人，各组的年龄和性别上基本相同，将实施例1-3的产品给1-3组的患者服用，将现有产品给4组的患者服用，每天3次每次2g并且采用温开水送服，2天为一个疗程，持续两个疗程，治疗结果见表1。
疗效判定标准：痊愈：发热症状完全消失，三个月内不再复发。好转：发热症状减轻一半以上。无效：发热症状症状没有减轻甚至加重。
表1
从表1可以看出，实施例1-3产品的治愈率和有效率均优于现有产品，治疗效果好。实施例1-3的产品在使用过程中，患者没有任何不适，患者在服药期间忌辛辣等刺激性食物，忌饮酒。
对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。
Claims (4)
1.一种用于治疗急性发热的药物，其特征在于，由以下原料按照重量份组成：辅料2-5份、牛磺酸5-10份、纤维素0.5-3份、维生素0.1-1.5份、氨基酸1-6份、泰诺林5-10份、布洛芬2-6份、大青叶汁液4-9份、体积分数为50-60％的乙醇溶液15-24份、青霉素1.5-4份和柴胡颗粒3-6份，大青叶汁液采用大青叶浸泡在5-8倍的质量分数为70％的乙醇中2-4次，每次浸泡4-5小时，合并浸泡液并且过滤，收集滤液得到。
2.根据权利要求1所述的用于治疗急性发热的药物，其特征在于，所述辅料采用淀粉、乳糖、糊精、木糖醇、微粉硅胶、蔗糖和葡萄糖的一种或者几种的混合物，纤维素采用微晶纤维素或者羧甲基纤维素。
3.根据权利要求1或2所述的用于治疗急性发热的药物，其特征在于，所述维生素采用维生素A、维生素B1、维生素C和维生素K的一种或者几种的混合物，氨基酸采用丝氨酸、赖氨酸、谷氨酸和天冬氨酸的一种或者几种的混合物。
4.一种如权利要求1-3任一所述的用于治疗急性发热的药物的制备方法，其特征在于，具体步骤如下：
步骤一，将泰诺林、布洛芬和柴胡颗粒混合在一起并且采用粉碎机粉碎，粉碎后的产物过30-50目筛子，得到第一混合物，留作备用；
步骤二，将牛磺酸、纤维素、维生素、氨基酸和青霉素放入乙醇溶液中，搅拌机在35-48摄氏度下以60-120rpm的转速搅拌20-45分钟，再进行减压浓缩至1:1，静置10-16小时后进行过滤，得到上清液和沉淀物；
步骤三，将大青叶汁液加入上清液中并且搅拌机在常温下以180-300rpm的转速搅拌50-90分钟，将搅拌均匀的产物放入干燥箱中，干燥箱在45-60摄氏度下进行干燥，得到第二混合物；
步骤四，将第一混合物、沉淀物和第二混合物混合均匀并且粉碎，再加入辅料制成胶囊剂、颗粒型冲剂或者片剂即可。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611107172.4A CN106491852A (zh) | 2016-12-06 | 2016-12-06 | 一种用于治疗急性发热的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611107172.4A CN106491852A (zh) | 2016-12-06 | 2016-12-06 | 一种用于治疗急性发热的药物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106491852A true CN106491852A (zh) | 2017-03-15 |
Family
ID=58330416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611107172.4A Withdrawn CN106491852A (zh) | 2016-12-06 | 2016-12-06 | 一种用于治疗急性发热的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106491852A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948715A (zh) * | 2014-04-23 | 2014-07-30 | 通化万通药业股份有限公司 | 一种小儿氨酚黄那敏颗粒 |
-
2016
- 2016-12-06 CN CN201611107172.4A patent/CN106491852A/zh not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948715A (zh) * | 2014-04-23 | 2014-07-30 | 通化万通药业股份有限公司 | 一种小儿氨酚黄那敏颗粒 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104026672A (zh) | 一种白药子清热解毒汤料及其生产方法 | |
| CN101732627A (zh) | 一种治疗失眠的中药组合物及制备方法 | |
| CN106491852A (zh) | 一种用于治疗急性发热的药物及其制备方法 | |
| CN106539996A (zh) | 一种用于治疗急性发热的西药组合及其制备方法 | |
| CN106491677A (zh) | 一种用于治疗慢性支气管炎的药物及其制备方法 | |
| CN103720778A (zh) | 扶正解毒药物 | |
| CN102114134A (zh) | 一种治疗牲畜及家禽疾病的中药组合物 | |
| CN102397533B (zh) | 一种治疗禽减蛋综合症的复方蜂胶组合物及其制备方法 | |
| CN101181448A (zh) | 治疗面瘫的口服中成药 | |
| CN103690617A (zh) | 一种清热解毒抗病毒散剂 | |
| CN102805785B (zh) | 一种太极油及其制备方法 | |
| CN105454550A (zh) | 一种青果清肺润喉茶及其生产方法 | |
| CN111632113A (zh) | 一种女性肾功能有修复功效的压片糖果 | |
| CN105998477A (zh) | 一种外用型中药组合物膏剂、制备方法、使用方法及应用 | |
| CN105213826A (zh) | 一种广昌白莲清热降压冲剂及生产方法 | |
| CN105748679A (zh) | 一种治疗猪热毒、痢疾的中药处方 | |
| CN103893456A (zh) | 一种治疗小儿蛔虫病的中药组方 | |
| CN105360470A (zh) | 一种老桑枝清肝明目茶及其生产方法 | |
| CN104939049A (zh) | 一种枇杷补脑健脑冲剂及生产方法 | |
| CN104000985A (zh) | 一种治疗小儿消化不良的药物及其制备方法 | |
| CN105360472A (zh) | 一种栝楼解热止渴茶及其生产方法 | |
| CN101361859B (zh) | 一种用于治疗脚气、脚痒的皮肤滋养护肤霜 | |
| CN105412803A (zh) | 治疗家禽腺胃炎的药物组合物及其制备方法 | |
| CN104940771A (zh) | 一种凤尾菇清热醒脑冲剂及生产方法 | |
| CN106511984A (zh) | 一种用于偏头疼的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170315 |
|
| WW01 | Invention patent application withdrawn after publication |